Achieve Life Sciences (NASDAQ:ACHV) Stock Crosses Above Two Hundred Day Moving Average of $4.47

Achieve Life Sciences, Inc. (NASDAQ:ACHV) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.47 and traded as high as $4.78. Achieve Life Sciences shares last traded at $4.53, with a volume of 93,710 shares.

Analysts Set New Price Targets

A number of research analysts have weighed in on ACHV shares. Oppenheimer reaffirmed an “outperform” rating and issued a $18.00 price target on shares of Achieve Life Sciences in a research note on Monday, April 1st. Lake Street Capital cut their price objective on shares of Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, March 5th. Finally, Jonestrading began coverage on Achieve Life Sciences in a report on Wednesday, April 17th. They set a “buy” rating and a $20.00 target price for the company.

Achieve Life Sciences Stock Down 3.7 %

The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 4.02. The company has a market capitalization of $155.15 million, a P/E ratio of -2.96 and a beta of 1.26. The firm’s 50 day moving average price is $4.51 and its two-hundred day moving average price is $4.47.

Achieve Life Sciences (NASDAQ:ACHV) last released its earnings results on Thursday, March 28th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.06. Equities research analysts forecast that Achieve Life Sciences, Inc. will post -0.94 EPS for the current year.

Institutional Trading of Achieve Life Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. CVI Holdings LLC acquired a new position in shares of Achieve Life Sciences during the 1st quarter worth approximately $2,578,000. Madison Park Capital Advisors LLC bought a new stake in Achieve Life Sciences in the 4th quarter valued at $41,000. Raymond James & Associates grew its holdings in Achieve Life Sciences by 6.0% in the 4th quarter. Raymond James & Associates now owns 154,829 shares of the biopharmaceutical company’s stock valued at $638,000 after buying an additional 8,729 shares in the last quarter. Finally, Manchester Financial Inc. increased its position in Achieve Life Sciences by 43.9% during the 3rd quarter. Manchester Financial Inc. now owns 18,600 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 5,675 shares during the period. Institutional investors and hedge funds own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.